Skip to main content
Clinical Trials/NCT02358746
NCT02358746
Unknown
Not Applicable

Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach a Randomized Controlled Trial

Erasmus Medical Center0 sites125 target enrollmentMay 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ventricular Tachycardia
Sponsor
Erasmus Medical Center
Enrollment
125
Primary Endpoint
Recurrence (Recurrence of any ventricular tachycardia)
Last Updated
11 years ago

Overview

Brief Summary

Rationale: Nowadays ventricular tachycardia (VT) ablation in structural heart disease is performed primarily by early referral; while at the same time we still struggle with the limited longterm ablation success of endocardial VT ablation. An underestimated number of VTs from ischemic substrate have an epicardial exit. However, one cannot accurately predict who is in need of epicardial ablation. The investigators hypothesise endo/epicardial substrate homogenization in a first approach to be superior to endocardial substrate homogenization alone, in terms of recurrence on follow-up.

Objective: To show superiority of a combined endo/epicardial approach compared to a stepwise approach in the ablation of ventricular tachycardia in a population with ischemic cardiomyopathy on VT recurrence.

Study design: Multicenter prospective open randomized controlled trial. Study population: All patients above 18 years with an ischemic cardiomyopathy being referred for a ventricular tachycardia ablation.

Intervention: One group undergoes endo/epicardial ablation and the other group has endocardial ablation only as a first approach.

Main study parameters/endpoints: The main study endpoint is the difference in recurrences of ventricular tachycardia on follow-up - clinical or on implantable cardioverter defibrillator (ICD) interrogation - between the two ablation groups; secondary endpoints are procedure success and safety.

Registry
clinicaltrials.gov
Start Date
May 2015
End Date
December 2019
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Astrid Hendriks

MD

Erasmus Medical Center

Eligibility Criteria

Inclusion Criteria

  • clinical indication for ablation of a monomorphic ventricular tachycardia referred to one of the participating ablation centers
  • history of ischemic heart disease
  • ICD carrier or ICD implantation planned after the ablation
  • informed written consent

Exclusion Criteria

  • current unstable angina as defined by current european guidelines
  • AMI \< 30 days or in case of incessant VT \< 14 days
  • absence of visualisation of the coronary anatomy (coronary angiogram /CT-angiogram)
  • significant coronary stenosis approachable and clinically relevant for intervention
  • presence of a mobile left ventricle thrombus seen on (contrast) echocardiography or MRI
  • previous pericarditis
  • presence of mitral/aortic mechanical valves prosthesis; previous coronary artery bypass graft; any other thoracic surgery that could cause pericardial adhesions
  • previous thoracic radiation therapy
  • contra-indication for general anaesthesia
  • age below 18 years

Outcomes

Primary Outcomes

Recurrence (Recurrence of any ventricular tachycardia)

Time Frame: 2 years

Recurrence of any ventricular tachycardia: any appropriate ICD therapy or VT \> 30 seconds of duration recorded by ICD interrogations or on clinical event recorded by electrocardiogram with an initial blanking period of 1 week after the ablation procedure

Secondary Outcomes

  • procedure success(2 years)
  • procedure related (serious) adverse events(30 days)
  • procedure time, fluoroscopy and radiofrequency time(one day)
  • time to recurrence to ventricular arrhythmia(2 years)
  • number of appropriate ICD therapy on follow-up(2 years)
  • number of ventricular arrhythmia related hospitalizations(2 years)
  • free of antiarrhythmic drugs on follow-up(2 years)
  • repeat procedure(2 years)
  • incessant VT or VT storm on follow-up(2 years)
  • mortality(2 years)

Similar Trials